Change over period: —
NSE · KIMS
KIMS
-10.8% from the 52-week high · +30.4% above the low
Krishna Institute of Medical Sciences Ltd. engages in the provision of healthcare services. The company is headquartered in Secunderabad, Telangana. The company went IPO on 2021-06-28. The Company’s departments include accident, Alzheimer center, andrology and infertility center, pediatric obesity, pediatric oncology, pediatric oncology and hematology center, pediatric orthopedics and rheumatology, pediatric renal center, pediatric surgical center, female urology center, fertility center, gastrointestinal oncology, general surgery, heart wellness center and hepatobiliary surgery center. Its technologies include 4-Arm HD da Vinci Robotic Surgical System, O-Arm Scanner, Novalis Tx Linear Accelerator, 3 Tesla MRI, EBUS, Spy Glass, Mako Robotic for Knee Replacement, and Impella. The Company’s institutes include the institute of Cardiac Sciences, Institute of Dental Science, Institute of Gastroenterology & Hepatology, Institute of Heart & Lung Transplantation, and Institute of Neuro Sciences.
The short version. KIMS reported revenue of ₹1,344 crore for Sep 2026, up 39.9% from a year earlier. Net profit was ₹75 crore (up 11.9% year on year). Return on equity was 10.7% in Mar 2026. Promoter holding was 32.66% in Sep 2026, down 6.16 points over 8 quarters.
1 · The price
How has the stock traded?
KIMS trades 10.8% below its 52-week high and 30.4% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1,344 cr.
Sep 2026 net profit of ₹75 cr.
1.4 pts lower than a year earlier.
Revenue compounded at 20.9% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1344 | 1180 | 1075 | 998 | 961 | 872 | 797 | 772 |
| Net profit | 75 | 42 | 42 | 53 | 67 | 79 | 102 | 92 |
| Net margin % | 5.6 | 3.5 | 4.0 | 5.4 | 7.0 | 9.0 | 12.8 | 12.0 |
| EPS (₹) | 1.79 | 0.99 | 1.06 | 1.33 | 1.68 | 1.96 | 2.54 | 2.31 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 3905 | 3035 | 2498 | 2198 | 1651 | 1330 |
| Net profit | 241 | 384 | 310 | 336 | 333 | 201 |
| Net margin % | 6.2 | 12.7 | 12.4 | 15.3 | 20.2 | 15.1 |
| EPS (₹) | 6.03 | 9.61 | 7.75 | 8.41 | 8.31 | 5.03 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 10.7% in Mar 2026; debt to equity is 1.44.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 10.7 | 18.0 | 17.0 | 20.1 |
| Return on capital % | 8.2 | 13.2 | 14.9 | 19.5 |
| EBITDA margin % | 20.8 | 26.9 | 26.0 | 29.0 |
| Net margin % | 6.1 | 12.5 | 12.3 | 15.1 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 20.9% | 24.0% |
| Profit CAGR | -10.5% | 3.7% |
4 · The owners
Who holds it, and are they adding?
Down 6.16 pts over 8 quarters.
Down 0.67 pts over 8 quarters.
Up 1.17 pts over 8 quarters.
+35 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 38.82 | 38.82 | 34.11 | 34.11 | 34.11 | 34.11 | 32.5 | 32.66 | -6.16 |
| FII | 15.68 | 15.45 | 15.54 | 15.03 | 14.33 | 14.57 | 14.74 | 15.01 | -0.67 |
| DII | 32.05 | 31.95 | 31.66 | 32.12 | 32.71 | 32.5 | 34.43 | 33.22 | +1.17 |
| Public | 13.45 | 13.78 | 18.69 | 18.74 | 18.85 | 18.82 | 18.33 | 19.11 | +5.66 |
Mutual fund holdings · Oct 2026
144 schemes hold this stock
109 the month before.
- Groww BSE Hospitals ETF8.56% of NAV
- Invesco India Pharma and Healthcare Fund4.38% of NAV
- Mirae Asset Healthcare Fund3.48% of NAV
- Kotak Small Cap Fund3.31% of NAV
- Invesco India Small cap Fund3.2% of NAV
- Kotak Business Cycle Fund3.09% of NAV
- Axis Services Opportunities Fund2.98% of NAV
- Axis Flexi Cap Fund2.9% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for KIMS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about KIMS
What is the KIMS share price?
KIMS (KIMS) last closed at ₹767.80, up 1.16% on the day. Its 52-week range is ₹582.10 to ₹850.65.
What is the market cap of KIMS?
KIMS has a market capitalisation of about ₹30,262 crore. Its price-to-earnings ratio is 145.1.
How are KIMS's latest results?
KIMS reported revenue of ₹1,344 crore for Sep 2026, up 39.9% from a year earlier. Net profit was ₹75 crore (up 11.9% year on year). Return on equity was 10.7% in Mar 2026. Promoter holding was 32.66% in Sep 2026, down 6.16 points over 8 quarters.
Who owns KIMS?
As of Sep 2026, shareholding was: Promoter 32.66%, FII 15.01%, DII 33.22%, Public 19.11%.
How many mutual funds hold KIMS?
144 mutual fund schemes held KIMS in October 2026. That compares with 109 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 13 Sep 2024 · Stock Split From Rs.10/- to Rs.2/-
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.